Recommendations of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic Drugs
暂无分享,去创建一个
Giuseppe Capovilla | G. Zaccara | R. Michelucci | E. Perucca | F. Albani | B. Bernardina | G. Capovilla | Gaetano Zaccara | Emilio Perucca | Bernardo Dalla Bernardina | Roberto Michelucci | Fiorenzo Albani
[1] M. Mikati,et al. Double‐Blind Randomized Study Comparing Brand‐Name and Generic Phenytoin Monotherapy , 1992, Epilepsia.
[2] E. Wyllie,et al. Increased seizure frequency with generic primidone. , 1987, JAMA.
[3] J. Macdonald. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product , 1987, Neurology.
[4] Vinod P. Shah,et al. The Bioinequivalence of Carbamazepine Tablets with a History of Clinical Failures , 1992, Pharmaceutical Research.
[5] R. Sachdeo,et al. GENERIC VERSUS BRANDED CARBAMAZEPINE , 1987, The Lancet.
[6] J. L. Herranz,et al. Impacto clínico y económico de los fármacos genéricos en el tratamiento de la epilepsia , 2005 .
[7] A. Richens,et al. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[8] J. Lowe,et al. Comparison of Steady‐State Blood Levels of Two Carbamazepine Formulations , 1989, Epilepsia.
[9] V. Preedy,et al. Scottish Intercollegiate Guidelines Network , 2010 .
[10] A. Cawood,et al. BIO‐AVAILABILITY AND DISSOLUTION OF THREE PHENYTOIN PREPARATIONS FOR CHILDREN , 1986, Developmental Medicine & Child Neurology.
[11] M. Duchowny,et al. Carbamazepine toxicity resulting from generic substitution , 1993, Neurology.
[12] T. Suppes,et al. Gastrointestinal side-effects after switch to generic valproic acid. , 1998, Pharmacopsychiatry.
[13] O. Pelkonen,et al. Interindividual variability in human drug metabolism , 2001 .
[14] K. Kraushaar,et al. Effects of switching from Depakene to generic valproic acid on individuals with mental retardation. , 1997, Mental retardation.
[15] R. Hartley,et al. Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability? , 1990, The British journal of clinical practice.
[16] B. Ballinger,et al. Bioavailability of phenytoin. A comparison of two preparations , 1975, European Journal of Clinical Pharmacology.
[17] G. Koch,et al. Untoward effects of generic carbamazepine therapy. , 1987, Archives of neurology.
[18] A. Guberman,et al. Generic Substitution for Brand Name Antiepileptic Drugs: A Survey , 2000, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[19] G. Krämer,et al. Risiken der neuen Aut-idem-Regelung für die Behandlung mit Antiepileptika , 2002 .
[20] P. Tammisto,et al. BIOAVAILABILTY OF PHENYTOIN , 1976, The Lancet.
[21] F. Bochner,et al. Factors involved in an outbreak of phenytoin intoxication. , 1972, Journal of the neurological sciences.
[22] K. Jain. Investigation and Management of Loss of Efficacy of an Antiepileptic Medication Using Carbamazepine as an Example , 1993, Journal of the Royal Society of Medicine.
[23] J. Takanashi,et al. Vascular neurology: A new neurologic subspecialty , 2005, Neurology.
[24] J. G. Dios,et al. Fármacos genéricos en el tratamiento de la epilepsia , 2005 .
[25] R. Reading,et al. Generic prescribing for epilepsy. Is it safe? , 1997, Seizure.
[26] M. Eichelbaum,et al. The bioavailability of phenytoin , 1977, Journal of Neurology.
[27] J. Manson,et al. Bioavailability of phenytoin from various pharmaceutical preparations in children. , 1975, The Medical journal of Australia.
[28] Timothy E. Welty,et al. Loss of Seizure Control Associated with Generic Substitution of Carbamazepine , 1992, The Annals of pharmacotherapy.
[29] F. Besag. Is Generic Prescribing Acceptable in Epilepsy? , 2000, Drug safety.
[30] G. Mathern,et al. Epilepsia , 1991, NEURO FUNDAMENTAL.
[31] W. O'reilly,et al. Plasma phenytoin levels produced by various phenytoin preparations. , 1975, The Medical journal of Australia.
[32] K. Tomaszewski,et al. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy , 2005, Epilepsy & Behavior.
[33] I. Leppik,et al. Compliance and variability of plasma phenytoin levels in epileptic patients , 1979 .
[34] A. Wilner. Therapeutic equivalency of generic antiepileptic drugs: results of a survey , 2004, Epilepsy & Behavior.
[35] J. French,et al. Comparative Bioavailability of a Generic Phenytoin and Dilantin , 1994, Epilepsia.
[36] A. Richens. Impact of Generic Substitution of Anticonvulsants on the Treatment of Epilepsy , 1997, CNS drugs.
[37] Assessment: Generic substitution for antiepileptic medication , 1990 .